IDG China Venture Capital Fund V Associates L.P. Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001709671

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 1 positions · Total reported value $104.64M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 100.0% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, IDG China Venture Capital Fund V Associates L.P. disclosed 1 equity positions with a combined reported value of $104.64M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RLX ($104.64M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, IDG China Venture Capital Fund V Associates L.P. opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 100.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest IDG China Venture Capital Fund V Associates L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

IDG China Venture Capital Fund V Associates L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 1 US equity positions with a combined value of $104.64M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 1 positions · $104.64M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RLX (RLX TECHNOLOGY INC) at 100.0%
  • Average position size: $104.64M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be maintaining a cautious approach, possibly reflecting market uncertainty or a preference for stability, as indicated by a reduction in its position in RLX Technology Inc. The reduction in shares could suggest a shift away from high-risk or speculative investments towards more conservative ones. 2. Key Moves: - Reduced: RLX Technology Inc. (RLX) by 3.6% (from 57,133,003 to 55,074,473 shares). - No New Positions: There were no new additions to the portfolio. 3. Portfolio Structure: - Passive/Active: The rebalancing seems more passive, with no new positions added, indicating a focus on maintaining existing holdings rather than actively seeking out new opportunities. - Sector Bias: The fund is heavily invested in the Health Care sector, as evidenced by the position in RLX, which is a technology company in the medical device space. - Risk Appetite: The reduction in shares of RLX suggests a conservative risk appetite, possibly due to concerns over the company's performance or market conditions. 4. Per-Holding One-Liner: - RLX: RLX Technology Inc. is a medical device company, specializing in respiratory care products and services. (unverified) 5. One-Sentence Style Summary: The fund maintained a conservative stance in Q2 2026, reducing its exposure to RLX Technology Inc. in the Health Care sector without adding new positions, reflecting a cautious and sector-focused investment approach.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 55.07M $104.64M 100.00%
100.00%
Reduce

FAQ

What did IDG China Venture Capital Fund V Associates L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, IDG China Venture Capital Fund V Associates L.P. reported 1 equity positions worth $104.64M in aggregate; its largest disclosed positions were RLX ($104.64M).

How large is IDG China Venture Capital Fund V Associates L.P.'s portfolio?

IDG China Venture Capital Fund V Associates L.P. reported $104.64M of long equity holdings across 1 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is IDG China Venture Capital Fund V Associates L.P.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/idg-china-venture-capital-fund-v-associates/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →